Register for our free email digests:
Latest From Clarus Therapeutics Inc.
Keeping Track: Clarus, Agile and Sunovion Look To Bounce Back From CRLs; FDA To Review Rituximab Biosimilar
The latest drug development news and highlights from our US FDA Performance Tracker.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
While Lipocine Inc. is at the nail-biting stage of development for its oral testosterone Tlando (LPCN 1021) – awaiting a US FDA approval decision – urologists continue to study testosterone therapy to determine whether treatment of hypogonadal men is safe with appropriate monitoring.
Labeling updates will also clarify approved uses and warn of possible increased risk of heart attack and stroke; impact on products in development unclear.
- Generic Drugs
- OTC, Consumer
- Therapeutic Areas
- Gynecological, Urological
- North America
- Parent & Subsidiaries
- TherapeuticsMD Inc.
- Senior Management
Robert Finizio, CEO
Dan Cartwright, CFO
Dawn Halkuff, Chief Commercial Officer
Sebastian Mirkin, MD, CMO
Yulii Bogatyrenko, SVP, Bus. Dev.
- Contact Info
Phone: (561) 961-1900
6800 Broken Sound Pkwy. NW
Boca Raton, FL 33487
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.